Tolebrutinib associated with long-term safety, efficacy in relapsing-remitting MS

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.
“In the MS field, we need treatments that can better target both peripheral and centrally mediated inflammation, and I think there is a lot of hope for [Bruton’s tyrosine kinase] inhibitors,” Jiwon Oh, MD, PhD, associate professor at the University of Toronto and medical director of the Multiple Sclerosis Program at St. Michael’s

BOSTON — Treatment with tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable disability through 120 weeks, according to research presented at the American Academy of Neurology annual meeting.
“In the MS field, we need treatments that can better target both peripheral and centrally mediated inflammation, and I think there is a lot of hope for [Bruton’s tyrosine kinase] inhibitors,” Jiwon Oh, MD, PhD, associate professor at the University of Toronto and medical director of the Multiple Sclerosis Program at St. Michael’s